Loading
A phase 3 trial of Olverembatinib run by Ascentage Pharma Group Inc., now recruiting.
Study of Olverembatinib (HQP1351) in Patients With CML-CP is a phase 3 interventional study registered as NCT06423911 by Ascentage Pharma Group Inc., with 333 participants planned, started 2024-02-05. Conditions listed: Chronic Myeloid Leukemia, CML, CML, Chronic Phase. No results are recorded here; the registry entry is the source.
Shares Olverembatinib, Ascentage Pharma, Small-molecule kinase inhibitors.
Shares Olverembatinib, Ascentage Pharma, Small-molecule kinase inhibitors.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML).
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML), Small-molecule kinase inhibitors.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML), Small-molecule kinase inhibitors.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML), Small-molecule kinase inhibitors.
Shares Olverembatinib, Ascentage Pharma.
Shares Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia (CML), Small-molecule kinase inhibitors.